MARKET

SYRE

SYRE

Spyre Therapeutics
NASDAQ
104.00
+1.09
+1.06%
After Hours: 104.00 0 0.00% 19:30 11/13 EST
OPEN
102.33
PREV CLOSE
102.91
HIGH
104.50
LOW
100.49
VOLUME
746.24K
TURNOVER
--
52 WEEK HIGH
110.64
52 WEEK LOW
21.63
MARKET CAP
9.88B
P/E (TTM)
-32.2551
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Roivant Sciences (ROIV) and Cogent Biosciences (COGT)
TipRanks · 22h ago
Should Wider Losses Require Action From Spyre Therapeutics (SYRE) Investors?
Simply Wall St · 1d ago
XBI, SYRE, EXEL, BIIB: ETF Outflow Alert
NASDAQ · 1d ago
Following Earnings Losses, Is Spyre Therapeutics (SYRE) Still Worth Its 11x P/B?
Simply Wall St · 3d ago
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Benzinga · 4d ago
Weekly Report: what happened at SYRE last week (1102-1106)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Spyre Therapeutics (SYRE) and Alnylam Pharma (ALNY)
TipRanks · 11/05 11:10
Spyre Therapeutics Faces Ongoing Dilution Risk and Strategic Constraints From Heavy Reliance on External Financing
TipRanks · 11/05 06:00
More
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).

Webull offers Spyre Therapeutics Inc stock information, including NASDAQ: SYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRE stock methods without spending real money on the virtual paper trading platform.